Cellectis Unveils Epigenetic Editing Technology with Over 90% Efficiency
Cellectis reveals new research on a TALE-based epigenetic editing technology that modifies gene expression without altering the DNA sequence, at the annual meeting of the American Society of Gene and Cell Therapy.
Introduction of the TALEM Platform at the ASGCT Conference
Cellectis will present its work on a TALE-based epigenetic editing approach in the form of a poster at the annual meeting of the American Society of Gene and Cell Therapy, which will be held from May 11 to 15 in Boston. The poster, titled 'TALE-based epigenetic modulators show sustained knock-down of target genes in T-cells and HEPG2 via a high-throughput multiplex screening platform', will be published on the Cellectis website on May 13, 2026, at 5 PM (New York time).
Gene Reduction Results Exceeding 90% in Two Cellular Models
TALEM are fusion proteins that combine a TALE-type DNA-binding domain with functional domains enabling the induction of epigenetic modifications. Unlike traditional genomic editing tools, this approach does not induce DNA breaks and does not alter the DNA sequence. Cellectis has developed a high-throughput screening system capable of quickly assembling and testing hundreds of TALEMs to identify the most effective combinations. This strategy was applied to two distinct genes: one highly expressed in hepatocytes, the other involved in the dysfunction and exhaustion of T-cells. In both cases, the approach achieved a reduction of more than 90% in gene activity, maintained stably throughout the study.
